Exploration on the Approach to Syndrome Differentiation and Treatment of Pediatric Infectious Mononucleosis Based on the "Sweat Pore-Qi and Liquid-Collaterals" Theory
10.13288/j.11-2166/r.2025.16.008
- VernacularTitle:基于“玄府-气液-络脉”理论探讨儿童传染性单核细胞增多症辨治思路
- Author:
Linlin LIU
1
;
Ying DING
1
;
Yongbin YAN
1
;
Yinglin DUAN
1
;
Yu LIU
1
Author Information
1. Hospital of Pediatrics，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou，450003
- Publication Type:Journal Article
- Keywords:
infectious mononucleosis;
pediatrics;
sweat pore;
qi and liquid;
collaterals
- From:
Journal of Traditional Chinese Medicine
2025;66(16):1668-1671
- CountryChina
- Language:Chinese
-
Abstract:
Based on the "sweat pore-qi and liquid-collaterals" theory， it is considered that the core pathogenesis of pediatric infectious mononucleosis lies in the obstruction of sweat pores， the failure of qi and liquid to disperse， and damage to the collaterals due to pathogenic toxins. Accordingly， the treatment principles proposed include unblocking the sweat pores， regulating qi and liquid， and smoothing the collaterals. In clinical practice， treatment is differentiated according to stages： initial， acute， and late stages. In the initial stage， invasion of warm pathogenic toxins into the lung defense leads to obstruction of the sweat pores， which should be treated by unblocking the sweat pores and expelling pathogens outward. In the acute stage， the obstruction of the sweat pores worsens， leading to the failure of qi and liquid dispersal， resulting in intense heat toxins with accumulation of dampness， phlegm， and blood stasis， which should be treated by promoting qi movement， resolving dampness and phlegm， clearing heat， detoxifying， and dispersing stasis to regulate qi and liquid. In the late stage， residual pathogens remain， with qi and yin deficiency and unsmooth collaterals， which should be treated by unblocking the collaterals， dissipating nodules， tonifying qi， and nourishing yin to smooth the collaterals. This approach may provide new insights for the clinical treatment of pediatric infectious mononucleosis.
